Nephrotoxicity of anticancer treatment
J Małyszko, K Kozłowska, L Kozłowski… - Nephrology Dialysis …, 2017 - academic.oup.com
Severe adverse systemic drug events occur commonly as a result of treatment of cancer
patients. Nephrotoxicity of chemotherapeutic agents remains a significant complication …
patients. Nephrotoxicity of chemotherapeutic agents remains a significant complication …
Renal cell cancer and chronic kidney disease
DL Saly, MS Eswarappa, SE Street… - Advances in chronic …, 2021 - Elsevier
The association between chronic kidney disease (CKD) and renal cell carcinoma (RCC) is
bidirectional and multifactorial. Risk factors such as hypertension, diabetes mellitus, obesity …
bidirectional and multifactorial. Risk factors such as hypertension, diabetes mellitus, obesity …
Characteristic morphological changes in anti‐VEGF therapy‐induced glomerular microangiopathy
F Pfister, K Amann, C Daniel, M Klewer… - …, 2018 - Wiley Online Library
Aims Agents targeting vascular endothelial growth factor (VEGF) have increasingly been
used for the treatment of advanced malignancies, and have been found to induce renal …
used for the treatment of advanced malignancies, and have been found to induce renal …
Renal toxicities of targeted therapies
With the incorporation of targeted therapies in routine cancer therapy, it is imperative that the
array of toxicities associated with these agents be well-recognized and managed, especially …
array of toxicities associated with these agents be well-recognized and managed, especially …
Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during …
S Muto, T Matsubara, T Inoue, H Kitamura… - International Journal of …, 2023 - Springer
The prevalence of CKD may be higher in patients with cancer than in those without due to
the addition of cancer-specific risk factors to those already present for CKD. In this review …
the addition of cancer-specific risk factors to those already present for CKD. In this review …
[HTML][HTML] Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon …
H Jia, C Thelwell, P Dilger, C Bird, S Daniels… - Thrombosis research, 2018 - Elsevier
Introduction Interferon (IFN)-α and IFN-β approved for treatment of chronic hepatitis C viral
infection and multiple sclerosis respectively have been linked to thrombotic microangiopathy …
infection and multiple sclerosis respectively have been linked to thrombotic microangiopathy …
Serum and urine biomarkers for human renal cell carcinoma
AL Pastore, G Palleschi, L Silvestri… - Disease …, 2015 - Wiley Online Library
Renal cell carcinoma (RCC) diagnosis is mostly achieved incidentally by imaging provided
for unrelated clinical reasons. The surgical management of localized tumors has reported …
for unrelated clinical reasons. The surgical management of localized tumors has reported …
[HTML][HTML] Immunoregulation mechanism of VEGF signaling pathway inhibitors and its efficacy on the kidney
J Li, XL Li, CQ Li - The American Journal of the Medical Sciences, 2023 - Elsevier
Angiogenesis and immunosuppression are closely related pathophysiologic processes.
Widely prescribed in malignant tumor and proliferative retinal lesions, VEGF signaling …
Widely prescribed in malignant tumor and proliferative retinal lesions, VEGF signaling …
[HTML][HTML] Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients
Carfilzomib (CFZ) is a non-reversible proteasome inhibitor approved for the treatment of
patients with relapsed and refractory myeloma (RRMM). Its use has been associated with …
patients with relapsed and refractory myeloma (RRMM). Its use has been associated with …
Thrombotic microangiopathy associated with proteasome inhibitors
A Lodhi, A Kumar, MU Saqlain… - Clinical kidney …, 2015 - academic.oup.com
The ubiquitin proteasome pathway plays a key role in cell cycle, function and survival.
Bortezomib (BTZ) and Carfilzomib (CFZ) are the first two inhibitors of the proteasome …
Bortezomib (BTZ) and Carfilzomib (CFZ) are the first two inhibitors of the proteasome …